Regeneron Acquires 23andMe Assets for Genetic Research
In May 19, RegeneronDealroom has a profile for this one. Try Dealroom →, a major player in biotechnology, announced a new step in its efforts to advance medicine: it is acquiring a part of 23andMe’s business. Known for its popular at-home DNA testing kits, 23andMe has gathered genetic data from millions of individuals. Now, Regeneron plans to use this information to better understand how genetics influence disease.
This agreement will give Regeneron access to 23andMe’s vast genetic database and research services. The goal is to help Regeneron speed up the discovery of new drugs and treatments by identifying genetic patterns linked to health conditions. This kind of insight can make it easier to develop medicines that are more targeted and effective.
The two companies have worked together before in research partnerships, but this acquisition marks a deeper commitment. It reflects a growing trend in the health and biotech industries: combining genetic data and technology with drug development to create more personalized care.
The deal is expected to close by the end of 2025, pending regulatory approval.
Source:
A.M.
